Drugs / RAGWEED
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01925729 | Oct 2013 → Mar 2019 | allergic rhinitis, otitis media | Cuneyt M. Alper | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05119751 Comparator | Oct 2021 → Apr 2022 | hypersensitivity reaction disease | Clinique Spécialisée en Allergies de la Capitale | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ragweed | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01925729 ↗ |
| Route | Intranasal | “ragweed -- 1000PNU intranasal spray” NCT01925729 ↗ |